Irvine launches "animal free" medium for neural cells citing CNS focused pharmas as key market

By Staff Reporter

- Last updated on GMT

iStock/bodym
iStock/bodym

Related tags: Brain

Irvine Scientific has launched a medium for neuronal cells for pharmaceutical firms developing regenerative medicines and drugs for central nervous system disorders.

The medium – Prime XV Neural Basal medium– is a serum-free, chemically-defined formula designed to increase the reproducibility of both human and rodent neural progenitors and neuronal cells.

According to the California, US-based supplier “the ability to culture primary and reprogrammed neural progenitors is offering neurological researchers new ways to screen drugs for toxicity, better understand brain cancer, and use patient cells for disease modelling to advance the understanding and treatment of neurological diseases such as Alzheimer’s, Parkinson’s and epilepsy.”

Irvine has been expanding its Prime XV range in recent years in line with developments in biopharmaceutical research.

Last January for example, the California, US headquartered firm launched a medium optimized for T-cell, citing growing biopharmaceutical industry interest in CAR-T (Chimeric Antigen Receptor transduced T) cells.

Products in the Prime XV range do not contain animal serum, which means they are not associated with either concerns about transmitted bovine diseases or about potential shortages.

Irvine is owned by Japan Energy Corporation, a subsidiary of Nippon Mining Holdings.

Related topics: Bio Developments

Related news

Show more